01 1Hangzhou Sinodo Pharm Technology Co.,Ltd
02 1Qingdao Biopeptek Co., Ltd.
01 2Larazotide
01 1U.S.A
02 1Blank
NDC Package Code : 73212-074
Start Marketing Date : 2023-05-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82907-993
Start Marketing Date : 2024-08-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
A Larazotide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Larazotide, including repackagers and relabelers. The FDA regulates Larazotide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Larazotide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Larazotide supplier is an individual or a company that provides Larazotide active pharmaceutical ingredient (API) or Larazotide finished formulations upon request. The Larazotide suppliers may include Larazotide API manufacturers, exporters, distributors and traders.
click here to find a list of Larazotide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Larazotide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Larazotide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Larazotide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Larazotide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Larazotide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Larazotide suppliers with NDC on PharmaCompass.
We have 1 companies offering Larazotide
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
